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Objective:
 
 The objective of this study was to evaluate the
health care costs associated with the treatment of a new
episode of depression with bupropion sustained release
(SR) rather than with other antidepressants (selective se-
rotonin reuptake inhibitors [SSRIs], tricyclic antidepres-
sants [TCAs], and serotonin norepinephrine reuptake in-
hibitors [SNRIs]).
 
Methods:
 
 This was a retrospective cohort study based on
the private-pay, fee-for-service 1997 and 1998 MED-
STAT MarketScan databases. Individuals were included if
they were 18 years of age or older, had an initial prescrip-
tion for an antidepressant under study with an index pre-
scription date between July 1997 and June 1998, and had
a claim for a diagnosis of depression diagnosis within 30
days of the index date. All patients’ claims from six months
before and after receiving their index antidepressant pre-
scription were examined. Total, outpatient, and pharmacy
costs were compared among antidepressant groups using
an intent-to-treat analysis with exponential regression
models and bootstrapped 95% confidence intervals.
 
Results:
 
 A total of 1771 patients were included in the
study cohort. The mean age was 41.6 years, and 69.5%
of subjects were female. Most patients (75%) continued
with the index antidepressant during the 6-month fol-
low-up period. Although the drug acquisition cost was
lowest for TCAs, total costs were significantly higher for
patients treated with TCAs than for those treated with
bupropion SR (
 
p
 
 
 

 
 .05). In comparison with bupropion
SR, patients initiating therapy with sertraline had signif-
icantly higher mental health payments (
 
p
 
 
 

 
 .05).
 
Conclusions:
 
 Initiating treatment of depression with
bupropion SR was associated with lower total mental
health care costs compared with TCAs and with sertra-
line. This study reaffirms that formulary and medical
decision-makers should consider the overall impact of
antidepressant treatment, including but not limited to
drug acquisition costs, other health care costs, and drug
efficacy and safety.
 
Keywords:
 
 antidepressants, bupropion SR, direct medi-
cal costs, retrospective analysis.
 
Introduction
 
Major depression is one of the most common ill-
nesses in the United States. Based on data from the
early 1990s, the National Comorbidity Survey es-
timated the lifetime prevalence of a major depres-
sive episode to be 17% [1]. The economic impact of
depression on society is substantial. The total cost of
depression in the United States was estimated to be
$43.7 billion in 1990, of which 28% was attributed
to direct medical costs [2]. A recent pharmacy bene-
fit report indicated antidepressants as the class of
drugs with the highest per-member-per-year expen-
ditures in managed care [3]. In the face of pressure
to contain health care costs, economic evaluations
of drug therapy should include an evaluation of
health care costs beyond acquisition cost.
Bupropion hydrocholoride sustained release
(Glaxo Wellcome’s Wellbutrin SR) is a norepineph-
rine and dopamine reuptake inhibitor (NDRI) that
does not affect serotonergic function directly. It has
been marketed in the United States for the treatment
of major depression since December 1996. It is
chemically unrelated to tricyclics (TCAs), selective
serotonin reuptake inhibitors (SSRIs), and other an-
tidepressant agents, although the exact mechanism
of action of bupropion SR remains unknown [4].
Previous clinical studies have established bu-
propion SR’s efficacy and tolerability in the treat-
ment of major depression [5–14]. The efficacy of
bupropion SR is similar to that of other antidepres-
sants [6–12,14], although bupropion SR is associ-
ated with fewer side effects [7,8,10–14]. A review
of the 1998 Physicians’ Desk Reference comparing
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the side-effect profiles of nine antidepressants (flu-
oxetine, paroxetine, sertraline, fluvoxamine, nefa-
zodone, bupropion SR, mirtazapine, venlafaxine,
and citalopram) identified bupropion SR as hav-
ing the least potential for gastrointestinal, central
nervous system, and sexual adverse effects [11]. A
clinical study that directly compared bupropion
SR and sertraline treatments for major depression
in outpatients confirmed that although both com-
pounds are well tolerated, symptoms of sexual
dysfunction, nausea, diarrhea, somnolence, and
sweating are associated with sertraline more often
than with bupropion SR [6]. A similar clinical trial
evaluating bupropion and trazodone efficacy and
side-effect profiles in outpatients with major de-
pression found that although bupropion was asso-
ciated with anorexia and anxiety, the trazodone
treatment group more often reported somnolence,
appetite increase, and edema [13]. Moreover, the
currently available antidepressants do not differ in
efficacy for the treatment of depression in either
the general population or in women, although
they do differ in terms of side-effect profile, toxic-
ity, and mechanism of action [15,16].
While the efficacy and tolerability of bupropion
SR is well established, its effect on health care
costs has not been examined. Thus, health care
costs associated with initiating treatment of new
episodes of major depression with bupropion SR
were compared with health care costs associ-
ated with initiating such treatment with TCAs
(clomipramine, desipramine, doxepin, imipramine,
nortriptyline, protriptyline, and trimipramine), SSRIs
(fluoxetine, paroxetine, and sertraline), and ven-
lafaxine.
 
Methods
 
Data Sources
 
Data from medical and pharmacy claims were ob-
tained from the MEDSTAT 1997 and 1998 Market-
Scan Private Pay Fee-For-Service database. Market-
Scan is a system of comprehensive and standardized
medical and prescription claims that applies to ap-
proximately 1 million employees and their depen-
dents across the United States who are covered by
indemnity health insurance, point-of-service (POS),
and preferred provider organization (PPO) managed
care plans. Previous research on depression has
made use of the MarketScan database [17–21].
 
Patient Cohort Selection
 
To be included in the analysis, patients had to be
at least 18 years of age and receive a study antide-
pressant between July 1, 1997 and June 30, 1998.
The date on which patients were first prescribed
antidepressant medication during the study period
is termed the 
 
index prescription date
 
 (IPD). The
study followed an “intent-to-treat” approach. Pa-
tients were required to have at least one claim
more than 6 months before the IPD as evidence
for continuous enrollment in the health plan prior
to and during the study. To ensure that patients
included in the study were prescribed antidepres-
sant medication for the treatment of depression,
only those patients who were diagnosed with de-
pression within 30 days prior to IPD were re-
tained. Both inpatient and outpatient records were
reviewed for the presence of any of the following
ICD-9-CM codes for depression: 296.2, 296.3,
300.4, 309.0, 309.1, 311. Antidepressant medica-
tions used in this study have various FDA-approved
indications, not all of which include the above de-
pression diagnostic codes, and there is consider-
able off-label use for treatment of other forms of
depression.
To ensure that only patients receiving treatment
for a new episode of depression were included in
the analysis, those fulfilling any of the following
criteria in the 6-month period prior to the IPD were
excluded: 1) patients who received a prescription
for any antidepressant (i.e., any study antidepres-
sant or any other antidepressants such as mono-
amine oxidase inhibitors (MAOIs), bupropion IR,
tricyclic, tetracyclic, dibenzoxapine, mirtazapine,
nefazodone, or trazodone); 2) patients who re-
ceived psychotherapy or electroconvulsive therapy
(ECT); 3) patients diagnosed with certain mental
health conditions, such as dementia, bipolar disor-
der, schizophrenia, psychotic disorder, and sub-
stance abuse (ICD-9-CM codes: 290–295; 296.0;
296.1; 296.1; 296.34; 296.4–296.9; 297; 298; 299;
301; 303; 304; 305; 331.0; 332; 317–319; and
797); and 4) patients treated with bupropion SR
with a concomitant diagnosis of tobacco-use dis-
order (ICD-9-CM 305.1), because bupropion SR
has been an approved aid for smoking cessation in
the United States since May 1997.
 
Economic Outcomes
 
Total health care costs for patients treated with
bupropion SR were compared with those for pa-
tients treated with the other study antidepressants
over the 6-month post-IPD period. Comparisons
in terms of cost components such as outpatient
and pharmacy costs were also made. Comparison
of inpatient costs was not performed separately,
owing to the small number of hospitalizations in
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the patient cohort. However, inpatient costs were
included in the total health care cost. Claims were
coded as mental health-related if one or more of
the diagnoses associated with the claim included
any ICD-9 code between 290.xx and 319.xx. To
provide additional insight into the cost differ-
ences, total health care and outpatient costs were
further divided into components related to mental
health and those not related to mental health.
Pharmacy costs were divided into costs of antide-
pressants, costs related to mental health, and costs
not related to mental health.
 
Other Covariates
 
Patient characteristics were compared among the
antidepressant groups. Demographic characteris-
tics including gender, age, type of insurance cover-
age (indemnity vs. managed care), geographic re-
gion (Northeast, North central, South, and West),
and the relationship of the patient to the employee
(self, spouse, or dependent) were assessed at the
IPD. The total number of unique major diagnostic
categories (MDCs) and psychiatric diagnostic groups
(PDGs) for concomitant physical and psychiatric
conditions during the 6 months prior to IPD were
used as a proxy for the overall physical and men-
tal health status of the patient [22]. A greater num-
ber of MDCs or PDGs in a patient’s chart reflects
worse physical and mental health, respectively.
The covariates considered in the regression mod-
els included demographics, health status, and depres-
sion diagnosis (major depression diagnosis; depres-
sion not elsewhere classified; neurotic depression;
and brief depressive episode). The full set of cova-
riates was used in all regression analyses of outpa-
tient, pharmacy, health care, and mental health-
related costs.
 
Statistical Analyses
 
Differences among the study antidepressant groups
in terms of demographics, insurance type, and co-
morbidities were examined using chi-square and
two-tailed 
 
t
 
-tests adjusted for multiple comparisons
at 
 

 
 
 

 
 0.05. SAS version 8.0 software (SAS Insti-
tute, Cary, NC, USA) was used to extract the final
analytical sample and to conduct descriptive anal-
yses. Statistical estimations were performed using
an exponential regression specification to account
for the non-negative nature of health care costs
[23]. The conditional mean of costs (P
 
i
 
 | X
 
i
 
) during
the 6 months following initiation of therapy for
the i (I 
 

 
 1, . . . ,N) individual was modeled as:
where 
 

 
 is a vector of parameters to be estimated,
X
 
i
 
 is a vector of individual specific covariates, and
 

 
i
 
 is an individual specific random error term.
Parameter estimates from the nonlinear regres-
sions were used to calculate the changes in costs of
initiating treatment for depression with other anti-
depressants in comparison with bupropion SR.
For instance, to calculate the cost difference of ini-
tiating patients on fluoxetine vs. bupropion SR,
we first obtained average total predicted payments
for all study patients, assuming that the entire
sample was started on fluoxetine, by using the for-
mula:
Next, we assumed that the full sample was started
on bupropion SR and obtained the average total
predicted cost by setting the value of the fluoxe-
tine dummy in the above formula to zero. The dif-
ference in average total predicted costs between
the two antidepressants constitutes the incremen-
tal effect of starting patients on fluoxetine vs. bu-
propion SR. Confidence intervals at 95% for the
estimated coefficients were obtained from boot-
strapping with 200 replications, because boot-
strapping is a convenient method for obtaining
empirical estimates of standard errors in the pres-
ence of heteroskedacticity [24]. Model estimations
and bootstrapping were carried out in STATA Ver-
sion 6.0 (Stata Corporation, College Station, TX,
USA).
 
Results
 
Patient Cohort Selection
 
A total of 1771 patients who were aged 18 years
or older and took a study index antidepressant be-
tween July 1, 1997, and June 30, 1998, met the
study’s inclusion criteria: receiving only one drug
at index prescription date (IPD); being eligible
during the 6 months before and after IPD; having
a claim with a diagnosis for depression within 30
days of IPD; and having no evidence of antide-
pressant therapy in the 6-month period preceding
IBD. Patients were excluded if they had an exclu-
sionary mental health diagnosis or procedure within
6 months prior to their IPD. Finally, seven addi-
tional bupropion SR patients were excluded be-
cause they had a claim for a diagnosis of tobacco-
E Pi Xi( ) βXi( )exp εi+=
Cost coefficient on fluoxetine dummy{exp=
 sum of coefficients of other covariates(+
 observed value of covariates× ) }
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use disorder (
 
n
 
 
 

 
 3) or they were unable to pro-
vide complete demographic information (
 
n
 
 
 

 
 4).
 
Patient Characteristics
 
Patient characteristics by antidepressant group are
presented in Table 1. Sixty-nine percent were fe-
male with a mean age of 42 years. One hundred
and fifteen patients initiated antidepressant therapy
with bupropion SR, 564 with fluoxetine, 393 with
paroxetine, 481 with sertraline, 145 with TCAs,
and 73 with venlafaxine. Fifty-eight percent of the
sample population was covered by indemnity-type
health insurance, and the remaining patients were
covered by managed care. The largest proportion
of patients (63%) lived in the North central region
of the United States. All antidepressant groups
were similar in terms of demographics and insur-
ance coverage with the exception of the paroxetine
group, which had significantly more females than
the bupropion SR group (70.7% vs. 56.5%; 
 
p
 
 
 

 
.05). The mean number of MDCs and PDGs was
2.9 and 0.5, respectively, for the overall patient
cohort. The mean number of MDCs and PDGs
was comparable across antidepressant groups with
the exception of patients receiving TCAs, who had
significantly more MDCs (3.46) than patients re-
ceiving bupropion SR (2.55) in the 6 months prior
to IPD (
 
p
 
 
 

 
 .05).
The mean health care costs by index antidepres-
sant are presented in Table 2. During the 6-month
post-IPD study period, TCA patients had signifi-
cantly higher mean total health care costs ($4258)
compared with patients who initiated therapy on
bupropion SR ($2373) (
 
p
 
 
 

 
 .05). The difference
was driven by the significantly higher total non-
mental health costs in TCA patients ($1561 per
bupropion SR patient vs. $3402 per TCA patient,
 
p
 
 
 

 
 .05). The mean total health care costs for bu-
 
Table 1
 
Summary of patient characteristics
 
All patients Bupropion SR Fluoxetine Paroxetine Sertraline TCAs Venlafaxine
No. of subjects 1771 115 564 393 481 145 73
Mean age (SD) 41.6 (11.9) 42.6 (11.8) 40.4 (11.9) 42.2 (11.9) 41.2 (12.0) 44.7 (11.0) 42.2 (10.9)
% Females 69.1 56.5 69.3 70.7* 70.1 69.0 72.6
Insurance type (%)
Indemnity 58.1 60.9 61.5 58.0 55.7 53.8 52.1
POS 14.7 13.9 14.4 16.8 14.3 15.9 8.2
PPO 27.2 25.2 24.1 25.2 29.9 30.3 39.7
Geographic region (%)
Northeast 5.2 6.1 4.4 5.6 5.8 2.1 9.6
North central 63.0 59.1 66.0 60.8 64.0 60.7 54.8
South 21.6 24.3 18.6 22.9 21.0 29.0 21.9
West 10.3 10.4 11.0 10.7 9.1 8.3 13.7
Member (%)
Employee 59.9 56.5 56.0 64.1 61.5 61.4 58.9
Dependents 40.1 43.5 44.0 35.9 38.5 38.6
Mean # MDCs (SD) 2.89 (2.12) 2.55 (1.79) 2.83 (2.06) 2.94 (2.08) 2.79 (2.09) 3.46 (2.46) 3.36 (2.19)
Mean # PDGs (SD) 0.49 (0.72) 0.55 (0.62) 0.53 (0.65) 0.56 (0.69) 0.48 (0.61) 0.46 (0.67) 0.77 (0.74)
 
* Significant at 
 
p
 
 
 

 
 .05 vs. bupropion SR. MDC, major diagnostic category; PDG: psychiatric diagnostic group.
 
Table 2
 
Unadjusted mean (SD) health care costs 6-months after index prescription date (US$)
 
Bupropion SR Fluoxetine Paroxetine Sertraline TCAs Venlafaxine
No. of subjects 115 564 393 481 145 73
Total health care cost ($) 2,373 (2,434) 2,549 (4,187) 2,685 (5,310) 2,665 (4,903) 4,258 (7,67djc@2)* 3,147 (4,500)
MH-related 813 (753) 984 (1,456) 895 (1,382) 1,118 (3,016) 856 (1,648) 991 (1,188)
NMH-related 1,561 (2314) 1,565 (3,945) 1,790 (4,985) 1,546 (3,724) 3,402 (7,370)* 2,156 (4,212)
Outpatient cost ($) 1,369 (1,846) 1,472 (2,604) 1,436 (2,099) 1,307 (2,111) 2,157 (3,663) 1,963 (3,412)
MH-related 379 (549) 433 (970) 446 (787) 412 (759) 443 (790) 534 (1,000)
NMH-related 990 (1,686) 1,039 (2,417) 989 (1,920) 896 (1,879) 1,714 (3,547) 1,429 (3,275)
Pharmacy cost ($) 826 (997) 751 (630) 678 (585) 702 (642) 917 (1,197) 847 (987)
MH-related 36 (94) 32 (97) 39 (102) 31 (103) 80 (179)* 35 (94)
NMH-related 432 (901) 289 (475) 322 (480) 325 (541) 654 (1,070)* 436 (876)
Antidepressant 358 (325) 430 (317) 318 (205) 346 (237) 183 (255)* 377 (252)
Index (%) 73 92* 82 85 34* 88
Other (%) 27 8* 18 15 66 12*
 
* Significant at 
 
p
 
 
 

 
 .05 vs. bupropion SR using chi-square test (categorical data) or 
 
t
 
-test (continuous data) adjusted for multiple comparisons. MH, mental health;
NMH, non-mental health.
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propion SR were not statistically different from
costs for those initiating therapy with an SSRI or
venlafaxine. The mean outpatient costs for bupro-
pion SR were not significantly different from those
incurred by patients using other antidepressants.
In addition, there were no statistically significant
differences between bupropion SR and other anti-
depressants in terms of mean total pharmacy
costs. Despite the lower drug acquisition costs of
TCAs, patients treated with TCAs had higher
mean mental health and non-mental health phar-
macy costs than patients treated with bupropion
SR. The proportion of antidepressant payments
that was attributable to the index antidepressant
for bupropion SR (75%) was significantly higher
than that for TCAs (34%).
Table 3 presents the coefficients for the regres-
sion models. Patients with indemnity insurance cov-
erage had significantly lower total mental health
pharmacy costs compared with those with man-
aged care coverage. In general, a greater comor-
bidity burden, as measured by the number of unique
MDCs in the prestudy period, was associated with
higher health care costs. Overall, a diagnosis for
major depression was associated with significantly
higher costs (total, mental health total, outpatient,
mental health outpatient, pharmacy, antidepres-
sant, and mental health pharmacy costs) when
compared with other types of depression. Initiat-
ing therapy with a TCA, as compared with bupro-
pion SR, was associated with higher total costs.
Initiating therapy with either fluoxetine, paroxet-
ine, or venlafaxine was not associated with a sig-
nificant cost difference compared with initiating
treatment with bupropion SR. Initiating therapy
with sertraline was associated with significantly
higher total mental health costs compared with
initiating therapy with bupropion SR.
Table 4 compares the health care costs associ-
ated with various antidepressants as initial ther-
apy for new episodes of depression with bupro-
pion SR and with each other during the 6-month
post-IPD period. The cost estimates were derived
from nonlinear models, and so the total health
care cost estimate will not necessarily equal the
sum of its components. Initiating treatment with a
TCA was associated with a significantly greater
total health care cost of $1497 per patient com-
pared with bupropion SR (
 
p
 
 
 

 
 .05), despite the
significantly lower acquisition antidepressant cost
for TCA (
 

 
$183). The higher total health care
cost of TCAs was primarily driven by the non-
mental health component of health care cost, total
outpatient cost, and mental health-related phar-
macy cost. Total health care costs did not differ
significantly in two-way comparisons of bupro-
pion SR vs. SSRIs and bupropion SR vs. venlafax-
ine. When the components contributing to health
care costs were considered, initiating therapy with
sertraline significantly increased the per-patient
mental health-related total health care cost by
$345 (
 
p
 
 
 

 
 .05). Bupropion SR was not signifi-
cantly different from fluoxetine, paroxetine, or
venlafaxine in any of the cost comparisons.
 
Discussion
 
During the past decade, the provision of health
care in the United States has shifted largely from
fee-for-service to managed care with the goal of
cost containment. During this period, increased
competition in the health care marketplace has
also occurred, and health care payers must com-
pete for quality while simultaneously controlling
costs. The growing importance of cost and quality
in the delivery of health care has encouraged eco-
 
Table 3
 
Parameter estimates of regression models
 
Costs
Total 
health care MH total NMH total Outpatient
MH 
outpatient
NMH 
outpatient Pharmacy Antidepressant
MH 
pharmacy
NMH 
pharmacy
Intercept 7.029* 6.862* 6.204 6.676* 5.845* 6.125* 5.771* 5.676*  2.005 4.433*
Female
 

 
0.2653
 

 
0.0813
 

 
0.4318*
 

 
0.1348 0.0424
 

 
0.2731
 

 
0.1205 0.0085
 

 
0.0160
 

 
0.3112*
Age 0.0098
 

 
0.0077 0.0174 0.00053
 

 
0.0078 0.0036 0.0178* 0.0051* 0.0273* 0.0313*
Indemnity
 

 
0.1879
 

 
0.0363
 

 
0.2670
 

 
0.0920
 

 
0.0959
 

 
0.0902
 

 
0.0693
 

 
0.0556
 

 
0.6136*
 

 
0.0901
Preperiod
PDG count
 

 
0.0601
 

 
0.0448
 

 
0.0494 0.1003 0.1715 0.1454
 

 
0.0296
 

 
0.0238 0.3400*
 

 
0.0905
MDC count 0.1464*
 

 
0.0065 0.2030* 0.1419*
 

 
0.0145 0.1910* 0.0776*
 

 
0.0129 0.0889 0.1426*
MDD 0.4846* 0.6239* 0.4352 0.3889* 0.6918* 0.2826 0.2624* 0.2744* 0.6385* 0.2080
Fluoxetine 0.0373 0.2535
 

 
0.0344 0.0749 0.2975 0.0266
 

 
0.0902 0.1714
 
0.2050 0.3304
Paroxetine 0.2006 0.1309 0.2728 0.0921 0.2861 0.0541 0.1913 0.1486 0.0409 0.2369
Sertraline 0.0658 0.3673* 0.0691 0.0888 0.1882 0.1940 0.1588 0.0610 0.3939 0.1925
TCA 0.4897* 0.0653 0.6748 0.4517 0.2687 0.5755 0.0168 0.6958* 0.7140 0.2472
Venlafaxine 0.2404 0.1705 0.2746 0.2935 0.2969 0.3018 0.0551 0.0076 0.0293 0.1271
* Significant at p  .05. MH, mental health; NMH, non-mental health.
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nomic assessments that not only include drug ac-
quisition costs, but also consider the impact of
drug therapy on overall health care utilization and
total health care costs. As such, many studies ex-
amining the effect of SSRIs on health care costs
have been published. However, to our knowledge,
this is the first study to investigate the economic
impact of bupropion SR relative to other antide-
pressants. By providing a comprehensive view of
the economic impact of commonly used antide-
pressants from a health care payer perspective,
this study supplements the existing literature on
the economic impact of antidepressant therapy.
There is considerable controversy about the abil-
ity to draw reliable inferences about treatment ef-
fects from observational studies. For example,
observational studies have been criticized for their
failure to control for the effects of unobserved
variables that may be correlated with both treat-
ment selection and outcomes, thereby generating
biased estimates of treatment effects [25,26]. How-
ever, at least two recent surveys of the literature
have found that treatment effects estimated from
observational studies have been found to be com-
parable to randomized, controlled clinical trials
[27,28]. With adequate adjustment for the observ-
able differences between treatment groups, we be-
lieve that analysis of medical and pharmacy claims
data can provide a naturalistic view of the health
care resource use patterns in a real-life setting. In
the current analysis, observable patient character-
istics that may confound the estimation of differ-
ences in health care payments (e.g., demographics,
insurance type, and health status) were controlled
to obtain an estimate of the effect of initial antide-
pressant treatment on 6-month health care costs.
Results from the analysis show that patients
who initiated therapy with TCAs had significantly
higher total health care costs than patients who
initiated antidepressant therapy with bupropion SR.
Several published studies have reported that health
care resource utilization was lower for patients
who initiated antidepressant therapy with SSRIs
rather than with TCAs [29–31]. Consistent with
these previous findings, the results of this study
suggest that the additional health care cost of initi-
ating therapy with a TCA outweighed the higher
acquisition cost of bupropion SR. A recently pub-
lished study on antidepressant therapies found
that the side-effect profiles of newer antidepres-
sants (SSRIs, bupropion SR, venlafaxine) varied
significantly from that of TCAs [10]. Anticholin-
ergic side effects (e.g., blurred vision, constipation,
dizziness, dry mouth, tremor, and urinary distur-
bance) that are commonly associated with TCAs
often require medical intervention. Therefore, the
differences in total health care cost between TCAs
and bupropion SR may be explained by differ-
ences in the side-effect profiles.
This study shows that patients initiating antide-
pressant therapy with bupropion SR do not have
significantly different total health care or total phar-
macy costs compared with those receiving SSRIs.
However, we have found that patients initiating
therapy with sertraline experienced significantly
higher total mental health-related health care costs
than patients initiating therapy with bupropion
SR. Previous studies suggested that bupropion SR
and the SSRIs were generally comparable in terms
of efficacy for the treatment of depression [6–8].
Other studies that directly compared bupropion
SR with sertraline found a greater percentage of
gastrointestinal disturbances and orgasmic dys-
function in patients treated with sertraline [7,8].
In general, the SSRIs have been found to have sim-
ilar side-effect profiles [32].
Table 4 Incremental costs and 95% confidence interval of initiating therapy with other antidepressants as compared to 
bupropion SR
Fluoxetine Paroxetine Sertraline TCA Venlafaxine
Inc.
cost 95% CI
Inc.
cost 95% CI
Inc.
cost 95% CI
Inc.
cost 95% CI
Inc.
cost 95% CI
Total health care cost 90 (577,757) 526 (210,1781) 161 (627,949) 1497 (52,3142) 644 (343,1856)
MH-related 225 (26,462) 109 (118,313) 345* (21,885) 52.51 (231,521) 145 (140,495)
NMH-related 51 (838,685) 447 (506,1535) 102 (904,681) 1467 (64,2972) 481 (648,1595)
Outpatient cost 105 (306,516) 130 (261,521) 114 (516,288) 768 (229,1766) 459 (169,1268)
MH-related 117 (42,276) 112 (15,239) 70 (55,195) 104 (53,424) 117 (97,410)
NMH-related 26 (356,408) 53 (322,428) 169 (549,211) 745 (55,1596) 337 (438,1112)
Pharmacy cost 72 (261118) 144 (337,476) 122 (320,76) 14 (272300) 45 (267,290)
Antidepressant 68 (3,140) 50 (121,20) 22 (96,53) 183* (264,103) 2.80 (94,100)
MH-related 7 (36,18) 2 (33,26) 12 (43,13) 38* (.10,75) 1.05 (37,26)
NMH-related 117 (290,30) 88 (274,127) 73 (255,117) 117 (156,390) 50 (292,193)
* Significant at p  .05 vs. bupropion SR. MH, mental health; NMH, non-mental health.
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The reader should bear in mind that the validity
of the current study’s conclusions is subject to all
the usual limitations of retrospective database
analyses. For example, quantifying the cost of an-
tidepressant-induced sexual dysfunction in a ret-
rospective claims study is difficult. It is almost
certainly the case, however, that the prevalence of
antidepressant-induced sexual dysfunction has been
underestimated in studies obtained from spontane-
ous patient reports [7,8,13,33]. Physicians and pa-
tients may be reluctant to discuss sexual dysfunc-
tion, and, as a result, it is underdiagnosed. In a
recent study that asked patients specifically about
sexual side effects, the reported incidence was very
high for all the SSRIs [34]. Antidepressant-induced
sexual dysfunction has received attention from the
medical community only during recent years. Given
the prevailing misconception that sexual dysfunc-
tion is a trivial or lifestyle problem, even when
treated, it is unlikely that sexual dysfunction or
drug-related side effects are coded appropriately.
This implies that medical claims data may have
significant limitations as a source of reliable infor-
mation to assess the economic impact of antide-
pressant-induced sexual dysfunction. On the other
hand, it is probably safe to assume that medical
claims will understate the magnitude of such an
impact. This is especially true when one considers
that unreported or untreated sexual dysfunction
may lead to medication noncompliance and re-
lapse of depression [33], which may then result
in increased mental health-related costs. Another
potential limitation of this study is its generaliz-
ability. The sample sizes for the bupropion SR,
TCAs, and venlafaxine groups were relatively
small compared with that of the SSRIs group.
Finally, the reader should note that study find-
ings are subject to concerns regarding selection
bias, endogeneity, and other statistical threats
to validity that are common to nonrandomized
studies.
Conclusions
Initiating treatment of depression with bupropion
SR is associated with lower total health-care costs
in comparison with initiating treatment with a
TCA or sertraline. The observed cost differences
may be a result of differences in tolerability of the
antidepressants. Study results will be informative
to clinicians and health care decision-makers in
evaluating the economic impact of antidepressant
therapy.
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